Molecular Profile | Unknown unknown |
Therapy | Linsitinib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | not applicable |
Create By | smockus |
Update By | smockus |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | Unknown unknown | Advanced Solid Tumor | not applicable | Linsitinib | Phase I | Actionable | In a Phase I trial, Linsitinib (OSI-906) was well-tolerated and resulted in stable disease in 41% (27/66) of patients with an advanced solid tumor and a partial response in two patients with adrenocortical carcinoma (PMID: 25208878). | 25208878 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(25208878) | Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. | Full reference... |